Aurora Cannabis

Unlike Canopy Growth (CGC) (WEED), Aurora Cannabis (ACB) (ACBFF) has not reported its recent earnings and has not announced its upcoming earnings date.

The company recently acquired MedReleaf (MEDFF) and CanniMed Therapeutics. The impact of these two companies will be something to watch whenever the company releases its earnings. To learn more about the acquisition, read MedReleaf Stock Rises on Aurora Cannabis Acquisition.

Aurora Cannabis Analysts' NTM Recommendations and Targets 2018-07-04

Price target

Aurora Cannabis closed at 9.30 Canadian dollars on July 4. It had a consensus price target of 9.63 Canadian dollars and a median price target of 9.50 Canadian dollars. That translates to an upside of 2%–3.5% over the most recent closing price.

Analyst recommendations

The current consensus mean price recommendation for Aurora Cannabis for the next 12-month period is a “buy,” with two analysts recommending a “strong buy” for the stock. One analyst continued to have a “buy” recommendation on the stock, and one analyst maintained a “hold” recommendation.

Note in the above chart that there were fewer analysts for Aurora Cannabis than for Canopy Growth or Aphria (APHQF). We’ll look at Aphria more closely in the next part of this series. That makes analysts’ ratings somewhat less reliable compared to stocks (MJ) that have coverage from more analysts.

Editor’s Note: As of July 6, 2018,  Echelon Wealth Partners analyst Russell Stanley raised his target price for shares of Canopy Growth Corp. (WEED-TCGC-N) to $30 from $22, but maintained a ‘sell’ rating for the stock, given its current price. He also rated The Hydropothecary Corp. (HEXO-T, “Speculative Buy” rating, $6.75 target) and Village Farms International (VFF-T, “Speculative Buy”, $15.00 target), as reported by the Globe and Mail, July 4th, 2018.